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Gram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent 
an increasing challenge due to emergence of antimicrobial resistance. Escherichia coli 
and Pseudomonas aeruginosa are among the most common cause of GN-PJI and 
ciprofloxacin is the first-line antibiotic. Due to emergence of fluoroquinolone resistance, 
we evaluated in vitro the activity of fosfomycin, ciprofloxacin, and gentamicin, alone and 
in combinations, against E. coli and P. aeruginosa biofilms. Conventional microbiological 
tests and isothermal microcalorimetry were applied to investigate the anti-biofilm activity 
of the selected antibiotics against standard laboratory strains as well as clinical strains 
isolated from patients with prosthetic joint associated infections. The biofilm susceptibility 
to each antibiotic varied widely among strains, while fosfomycin presented a poor anti-
biofilm activity against P. aeruginosa. Synergism of two-pair antibiotic combinations was 
observed against different clinical strains from both species. Highest synergism was found 
for the fosfomycin/gentamicin combination against the biofilm of E. coli strains (75%), 
including a gentamicin-resistant but fosfomycin-susceptible strain, whereas the gentamicin/
ciprofloxacin combination presented synergism with higher frequency against the biofilm 
of P. aeruginosa strains (71.4%). A hypothetical bacteriolysis effect of gentamicin could 
explain why combinations with this antibiotic seem to be particularly effective. Still, the 
underlying mechanism of the synergistic effect on biofilms is unknown. In conclusion, 
combinatorial antibiotic application has shown to be more effective against biofilms 
compared to monotherapy. Further in vivo and clinical studies are essential to define the 
potential treatment regimen based on our results.
Keywords: Escherichia coli, Pseudomonas aeruginosa, biofilm-associated infection, antibiotic activity, synergism, 
clinical isolates, antibiotic resistance, isothermal microcalorimetry
INTRODUCTION
Gram-negative (GN) rods cause about 10% of periprosthetic joint infection (PJI) and represent 
an increasing treatment challenge due to the emergence of resistance worldwide (Shah et  al., 
2016; Thompson et  al., 2018). Enterobacteriaceae are most frequently isolated in GN-PJI, 
followed by Pseudomonas aeruginosa (Fantoni et al., 2019). GN-PJI can occur after hematogenous 
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seeding from a distant infectious focus (i.e. urinary or intestinal 
tract) or can be  introduced during arthroplasty and manifest 
in the early postoperative period (Sendi et al., 2010). Over a period 
of a few years (2003–2012), the occurrence of PJIs due to 
multidrug-resistant GN bacteria has increased significantly, in 
the case of E. coli, from 2 to 4.3%, and for P. aeruginosa, 
from 0.7 to 1.8% (Benito et al., 2016). Antimicrobial resistance 
in GN rods is increasing at both, community and hospital 
levels, and is often associated with treatment failure (Virginio 
et  al., 2019). The worldwide rise of carbapenem-resistant GN 
bacilli is of major concern for the public health. While formally 
this problem was mostly related to Pseudomonas and Acinetobacter 
species, the rising trend in E. coli may lead to almost untreatable 
community-acquired infections (Tangden and Giske, 2015).
In spite of its vast impact on patients and the health-care 
system (Haddad et  al., 2017), the management of GN-PJI is 
difficult due to the lack of a “gold standard” treatment strategy 
(Zmistowski et al., 2011; Goel et al., 2017). In fluoroquinolone-
susceptible GN rods, ciprofloxacin is recommended for PJI 
(Sousa and Abreu, 2018). However, the growing quinolone-
resistance in GN bacteria makes the treatment of GN-PJI more 
challenging complicating the clinical outcome (Rodriguez-Pardo 
et  al., 2014; Benito et  al., 2016). Due to unmet medical needs 
of currently available antibiotics, combination therapy has been 
investigated as an alternative strategy for GN-PJI treatment 
(Taha et  al., 2018). Especially, revival of older antibiotics such 
as fosfomycin gained attention for treatment of multi-drug 
resistant GN rods (Walsh et  al., 2016).
Beside antimicrobial resistance, treatment of PJI is challenged 
by the microbial persistence on the surface of implants forming 
biofilms (Taha et  al., 2018). In biofilms, microbes exhibit 
“phenotypical resistance” to standard antibiotics (Donlan and 
Costerton, 2002). Therefore, it is essential to look at possible 
anti-biofilm activities of single or combined antibiotics. Several 
pre-clinical investigations of fosfomycin combination therapy 
have shown synergistic activity against biofilms of GN bacteria 
(Falagas et  al., 2016), particularly in combination with 
fluoroquinolones or aminoglycosides (Michalopoulos et  al., 
2011; Corvec et  al., 2013). Nevertheless, no systematic studies 
investigated these combinations against P. aeruginosa and 
Escherichia coli biofilms in the same experimental settings. 
Thus, we  focused on combinations involving fosfomycin, 
ciprofloxacin, and gentamicin as representatives of the above-
mentioned antibiotic classes. These three antibiotics present a 
bactericidal effect against bacteria showing different mechanisms 
of action. Fosfomycin has a unique mode of action inhibiting 
irreversibly an early stage of bacterial cell wall biosynthesis 
(Dijkmans et al., 2017), whereas ciprofloxacin inhibits bacterial 
DNA replication (Thai and Zito, 2019) and gentamicin inhibits 
the bacterial protein synthesis (Kumar et  al., 2008).
Accurate experimental data from the investigation of 
combinatorial therapy with paired antibiotics might bring new 
evidences on their potential in the treatment of GN-PJI. Hence, 
we  evaluated the in vitro activity of single and combinations 
of fosfomycin, ciprofloxacin, and gentamicin against planktonic 
and biofilms of P. aeruginosa and E. coli strains, including 
resistant clinical isolates obtained from patients with prosthetic 
joint associated infections, by using conventional microbiological 
tests and isothermal microcalorimetry.
MATERIALS AND METHODS
Bacterial Strains
E. coli (ATCC 25922) and P. aeruginosa (ATCC 27853) 
laboratory standard strains were used in this study. Moreover, 
eight E. coli and seven P. aeruginosa clinical isolates obtained 
from consecutive patients diagnosed with PJI between 2015 
and 2017 were used for this study. For the diagnosis of 
PJI, the PRO-IMPLANT diagnostic criteria were used (Li 
et  al., 2018; Izakovicova et  al., 2019). The clinical isolates 
were used from the biobank collection, which is part of 
the prospective institutional PJI cohort. The study was 
approved by the institutional ethical committee (EA1/040/14) 
and was conducted in accordance with the most recent 
iteration of the Declaration of Helsinki. According to the 
ethical approval, participants’ informed consent was waived 
and all data were pseudonymized. Bacteria were stored at 
−80°C using a cryovial bead preservation system (Microbank; 
Pro-Lab Diagnostics, Canada).
Antimicrobial Agents
Fosfomycin (5  g; InfectoPharm, Heppenheim, Germany) was 
provided as purified powder by the manufacturer. Ciprofloxacin 
injectable solution (2  mg/ml; Fresenius Kabi GmbH, Bad 
Homburg, Germany) and gentamicin injectable solution (40 mg/
ml; Ratiopharm GmbH, Ulm, Germany) were purchased from 
the respective manufacturers. Stock solutions of appropriate 
concentrations were prepared in sterile 0.9% saline.
Etest
Etest (bioMerieux, Marcy-l’Étoile, France) was performed in 
Mueller-Hinton agar (MHA) (Becton, Dickinson and Company, 
Germany) following the manufacturer’s instructions. The 
minimum inhibitory concentration (MIC) was determined as 
the concentration at which the inhibition ellipse intersected 
the scale of the strip after incubation at 37°C for 24  h. To 
evaluate the susceptibility, the antimicrobial susceptibility 
breakpoints from the CLSI (CLSI, 2015) were used. All 
experiments were performed in triplicates.
Broth Macrodilution Assays
The MIC and the minimum bactericidal concentration (MBC) 
phase were determined for fosfomycin, ciprofloxacin, and 
gentamicin by the broth macrodilution assay (BMD) in cation-
adjusted Mueller-Hinton broth (CAMHB) (BD, Le Pont de 
Claix, France), according to the Clinical and Laboratory Standards 
Institute (CLSI) guidelines (CLSI, 1999). An inoculum of 
approximately 5  ×  105  CFU/ml were used. Two-fold serial 
dilutions of each antibiotic were prepared in 1  ml medium 
in plastic tubes and incubated for 24  h at 37°C. The MIC 
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was defined as the lowest concentration of antibiotic that 
completely inhibited visible growth.
After the incubation, all tubes without visible growth were 
vigorously vortexed, aliquots of 100  μl were plated on Tryptic 
Soy Agar (TSA) (Oxoid, Basingstoke, UK) plates, and the 
numbers of bacteria were determined. The MBC was defined 
as the lowest antimicrobial concentration that killed ≥99.9% 
of the initial bacterial inoculum after 24  h. The medium was 
supplemented with 25  mg/L glucose-6-phosphate for testing 
of fosfomycin. Glucose-6-phosphate induces the transport 
system via which fosfomycin is actively absorbed into the 
bacteria (Dijkmans et al., 2017). All experiments were performed 
in triplicates.
Assessment of Antimicrobial Activity by 
Isothermal Microcalorimetry and 
Sonication/Colony-Counting
The antimicrobial activity of fosfomycin, ciprofloxacin, and 
gentamicin against either E. coli or P. aeruginosa ATCC strains 
was determined by isothermal microcalorimetry (IMC) as 
described previously (Butini et  al., 2018). Briefly, planktonic 
bacteria (5  ×  105  CFU/ml) were treated with serial dilutions 
of antibiotics in CAMHB, and production of heat was measured 
for 24  h. The minimum heat inhibitory concentration (MHIC) 
was defined as the lowest concentration of antibiotic able to 
suppress the metabolic heat production of planktonic bacteria.
E. coli and P. aeruginosa biofilm formation was assessed by 
incubating porous glass beads (ROBU®, Hattert, Germany) in 
inoculated CAMHB with 2–3 colonies of the corresponding 
bacteria at 37°C. The ratio between beads and diluted bacterial 
suspension was 1 bead:1  ml, with a maximum of 10 beads 
per 50  ml Falcon tube. After 24  h incubation, beads were 
washed three times with sterile 0.9% saline to remove planktonic 
bacteria and exposed to serial dilutions of antibiotic in 1  ml 
of CAMHB and incubated for a further 24  h at 37°C. The 
media were supplemented with 25  mg/L glucose-6-phosphate 
for fosfomycin testing. After exposure to antibiotics, beads were 
washed three times with 0.9% saline, placed in glass ampoules 
containing 3 ml of CAMHB and introduced into the calorimeter 
(thermal activity monitor, model 3102 TAM III; TA Instruments, 
New Castle, USA). Sterile beads were used as negative control. 
Production of heat was recorded for 48  h to detect bacterial 
activity. The minimum biofilm bactericidal concentration (MBBC) 
was defined as the lowest concentration of antibiotic that 
strongly reduced biofilm cells viability and led to the absence 
of heat flow production after 48  h of incubation at 37°C.
Moreover, the biofilm-eradicating activity of these three 
antibiotics on clinical isolates from both species was evaluated 
by sonication and colony-counting as in a previous study 
(Gonzalez Moreno et al., 2019). The minimum biofilm eradicating 
concentration (MBEC) was defined as the lowest concentration 
of antibiotic required to kill all sessile cells resulting in the 
appearance of no colony after plating sonication fluid (detection 
limit: <20  CFU/ml).
The synergistic effect of antibiotic combinations was 
evaluated against both ATCC species following the IMC 
assay as described above and through CFU counting of the 
sonicated beads. The synergistic activity was evaluated by 
calculation of the fractional biofilm eradication concentration 
index (FBECI) as described in a previous study (Dall et  al., 
2018), where a FBECI of ≤0.5 indicates a synergistic effect. 
The FBECI was calculated following the equation: 
FBECI  =  FBECI A + FBECI B  =  MBECA combination/
MBECA alone + MBECB combination/MBECB alone, where 
MBECA combination and MBECB combination are the MBEC 
of compound A in the presence of B and compound B in 
the presence of A, respectively; MBECA alone and MBECB 
alone are the FBECI of compound A and compound B, 
respectively.
Data from IMC were analyzed by the manufacturer’s software 
(TAM Assistant; TA Instruments) and Prism 7.0 (GraphPad 
Software, La Jolla, CA). All experiments were performed 
in triplicates.
RESULTS
Activity of Antibiotics Against E. coli and 
P. aeruginosa ATCC Strains
The antimicrobial activity of fosfomycin, ciprofloxacin, and 
gentamicin against planktonic and sessile E. coli and P. aeruginosa 
ATCC strains was assessed using BMC, Etest, IMC (Figures 1, 2) 
and by plating of sonication fluid. Table  1 summarizes the 
susceptibilities of both species.
The observed MIC values evaluated by Etest and BMD were 
comparable to those obtained by IMC. Both ATCC strains 
were susceptible to all three tested antibiotics. Ciprofloxacin 
was the most active antibiotic against planktonic bacteria from 
both strains, followed by gentamicin. Fosfomycin showed a 
remarkable lower bactericidal activity against P. aeruginosa with 
MIC and MBC values 16 and 64 times higher respectively 
compared to E. coli.
Gentamicin was the most active antibiotic against the biofilm 
of both strains presenting a MBBC of 16 μg/ml (Figures 2E,F), 
whereas ciprofloxacin showed a notable higher anti-biofilm 
activity against E. coli (MBBC  =  16  μg/ml) compared to P. 
aeruginosa (MBBC  =  512  μg/ml) (Figures 2C,D). Fosfomycin 
exhibited a poor anti-biofilm activity against both tested ATCC 
strains (Figures 2A,B).
Results showed that the concentrations of antibiotics necessary 
to completely eradicate the biofilm (MBEC) of both ATCC 
strains correlated with the bactericidal concentrations observed 
by calorimetry (MBBC) for all the tested antibiotics.
Anti-biofilm Activity of Combined 
Antibiotics Against E. coli and 
P. aeruginosa ATCC Strains
The synergistic effect of two-pair antibiotics against biofilm of 
both ATCC strains was investigated by IMC combining fosfomycin/
ciprofloxacin, fosfomycin/gentamicin, and gentamicin/ciprofloxacin. 
Results are summarized in Table  2. Calorimetric curves are 
depicted in Figure 3.
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The strongest synergistic effect was observed when gentamicin 
was combined with fosfomycin (FBEC  =  0.06) against E. coli 
biofilm followed by the combination of gentamicin with 
ciprofloxacin, whereas these two antibiotic combinations showed 
similar synergistic effect against P. aeruginosa biofilm. Fosfomycin/
ciprofloxacin combination did not show synergism against the 
biofilm of both strains.
Antibiotic Susceptibility of E. coli and 
P. aeruginosa Clinical Strains
The MIC of E. coli and P. aeruginosa clinical strains to fosfomycin, 
ciprofloxacin, and gentamicin was determined by Etest. 
The results are summarized in Tables  3 and 4.
E. coli and P. aeruginosa strains were considered susceptible 




FIGURE 1 | Microcalorimetry analysis of planktonic bacteria exposed to serial antibiotic concentrations for 24 h. Numbers represent concentrations (in μg/ml) of 
fosfomycin (A,B), ciprofloxacin (C,D), and gentamicin (E,F) against E. coli ATCC 25922 (left column) and P. aeruginosa ATCC 27853 (right column). Circled values 
represent the MHIC. GC, growth control; NC, negative control. Data of a representative experiment are reported.
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MIC ≤1 μg/ml and to gentamicin when MIC ≤4 μg/ml according 
to CLSI (CLSI, 2015).
Most strains were susceptible to the tested antibiotics, 
except Ec6 (resistant to ciprofloxacin and gentamicin), Ec7 
(resistant to fosfomycin and ciprofloxacin), Ec8 (resistant 
to fosfomycin and gentamicin), Pa 6 (resistant to gentamicin), 
and Pa 7 (resistant to ciprofloxacin).
Ciprofloxacin exhibited the lowest MIC in sensitive strains 
for both bacterial species (MIC range 0.008–0.25 μg/ml), whereas 




FIGURE 2 | Microcalorimetry analysis of biofilm bacteria after exposure to serial antibiotic concentrations for 24 h. Numbers represent concentrations (in μg/ml) of 
fosfomycin (A,B), ciprofloxacin (C,D), and gentamicin (E,F) against E. coli ATCC 25922 (left column) and P. aeruginosa ATCC 27853 (right column). Circled values 
represent the MBBC. GC, growth control; NC, negative control. Data of a representative experiment are reported.
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E. coli (MIC range 0.064–1 μg/ml) than P. aeruginosa (8–48 μg/
ml). Gentamicin-susceptible strains from both species presented 
similar susceptible profile with a MIC range of 0.5–3  μg/ml.
Synergistic Effect of Antibiotic 
Combinations Against E. coli and 
P. aeruginosa Clinical Strains
The same two-pair antibiotic combinations tested against the 
ATCC strains were used to evaluate their ability to eradicate 
biofilms from clinical strains by sonication/colony counting. 
Tables  5 and 6 summarize the results of the MBEC for single 
and combined antibiotics against E. coli and P. aeruginosa 
clinical strains.
The biofilm susceptibility to each antibiotic varied widely 
among clinical isolates. Among the eight tested E. coli 
isolates, synergism based on fosfomycin/ciprofloxacin 
combinations was observed in two isolates (25%), while 
the combinations fosfomycin/gentamicin and gentamicin/
ciprofloxacin resulted synergistic in six (75%) and three 
isolates (37.5%), respectively.
Moreover, the fosfomycin/gentamicin combination showed 
a synergistic effect against Ec6, a gentamicin-resistant but 
fosfomycin-susceptible E. coli strain, whereas the synergistic 
effect was not observed when the fosfomycin/gentamicin 
combination was tested against Ec7, a fosfomycin-resistant but 
gentamicin-susceptible E. coli strain.
On the other hand, the synergism of gentamicin/ciprofloxacin 
was observed in five P. aeruginosa isolates (71.4%), while four 
isolates (57.1%) were susceptible to the combination of either 
fosfomycin/ciprofloxacin or fosfomycin/gentamicin.
DISCUSSION
Fluoroquinolones are the first choice as anti-biofilm antibiotics 
for the treatment of GN-PJI (Boyle et  al., 2019). However, 
emergence and spread of resistance to fluoroquinolones and 
aminoglycosides has decreased the existing treatment options 
for GN infections (Tucaliuc et  al., 2015). Combination therapy 
with fosfomycin has been recommended, particularly against 
fluoroquinolone resistant organisms (Boyle et  al., 2019). 
Nonetheless, there is a lack of systematic studies investigating 
antibiotic combinations under the same experimental settings 
on GN biofilms. In this study, we  have generated original data 
showing synergistic activity of two-pair antibiotic combinations 
against either E. coli or P. aeruginosa biofilms in vitro.
Conventional (Etest, BMD and colony counting) and 
nonconventional (IMC) laboratory tests were applied to evaluate 
the susceptibility to antibiotics of either planktonic or biofilm 
bacteria. As seen also in previous studies (Gonzalez Moreno 
et  al., 2017, 2019), the MHIC values obtained by IMC showed 
consistency to the MIC values obtained by BMD and Etest, 
proving the reliability of IMC for antimicrobial testing on large 
TABLE 2 | MBBC and FBEC values for fosfomycin (FOS), ciprofloxacin (CIP), and gentamicin (GEN) in combination against E. coli and P. aeruginosa.
Antibiotic E. coli (ATCC 25922) P. aeruginosa (ATCC 27853)
MBBC (μg/ml) FBEC (interpretation) MBBC (μg/ml) FBEC (interpretation)
FOS + CIP 128 + 8 0.75 (NS) 256 + 256 0.75* (NS)
FOS + GEN 2 + 1 0.06 (S) 256 + 2 0.38* (S)
GEN + CIP 1 + 2 0.19 (S) 4 + 8 0.26 (S)
MBBC, minimal biofilm bactericidal concentration; FBEC, fractional biofilm eradication concentration; S, synergism, NS, no synergism; *MBBCFOS of P. aeruginosa was considered 
equal to 1,024 μg/ml for FBEC calculations.
TABLE 1 | Antimicrobial susceptibility of planktonic and adherent E. coli and P. aeruginosa determined by conventional broth macrodilution (BMD), Etest, isothermal 
microcalorimetry (IMC), and sonication/colony-counting.
E. coli ATCC 25922
Antibiotic Etest BMD IMC Sonication
MIC MIC MBC MHIC MBBC MBEC
Fosfomycin 1 2 4 2 512 512
Ciprofloxacin 0.012 0.008 0.016 0.016 16 16
Gentamicin 0.5 0.5 4 1 16 16
P. aeruginosa ATCC 27853
Antibiotic Etest BMD IMC Sonication
MIC MIC MBC MHIC MBBC MBEC
Fosfomycin 16 32 256 32 >1,024 >1,024
Ciprofloxacin 0.25 0.25 1 0.5 512 512
Gentamicin 1 0.5 4 1 16 16
Concentration values are expressed in μg/ml.
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scale. Moreover, the concentrations of antibiotics needed to 
eradicate biofilms were analogous to those showing biofilm 
bactericidal activity by IMC.
As already reported for many microorganisms (Stewart, 
2015), in our study, the eradication of GN biofilms required 
considerably higher concentrations of all three tested antibiotics 
(4 to 2,723-fold higher) compared with the killing of their 
planktonic bacteria. Fosfomycin had no anti-biofilm activity 
against P. aeruginosa strains despite the use of high concentrations 
of antibiotic (up to 1,024 μg/ml) (Table 6). These results suggest 
that outcomes obtained on planktonic cells cannot be transferred 
to biofilms, underling the importance of developing 
standardize methods to evaluate antimicrobial activity on biofilms 




FIGURE 3 | Evaluation of synergistic activity of paired antibiotics by IMC against E. coli ATCC 25922 (A,C,E) and P. aeruginosa ATCC 27853 (B,D,F) biofilms. 
Numbers represent concentrations (in μg/ml). Circled values represent the MBBC. GC, growth control; NC, negative control; FOS, fosfomycin; GEN, gentamicin; 
CIP, ciprofloxacin. Data of a representative experiment are reported.
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combination with sonication as reliable methods for the in 
vitro analysis of bacterial biofilms (Butini et  al., 2018).
In biofilm infections, where antimicrobial monotherapies 
are not effective or not applicable due to the rapid development 
of antibiotic resistance (Wu et  al., 2015; Greimel et  al., 2017; 
Xu et  al., 2018), the use of antibiotic combinatorial therapies 
has been shown to be particularly relevant due to the potential 
synergy between drugs (Wu et  al., 2015). Therefore, we  also 
investigated the in vitro synergistic activity of paired antibiotics 
against E. coli and P. aeruginosa ATCC strains and clinical isolates.
A study limitation is the lack of a full chequerboard analysis 
for antibiotic combinations, which could bring more insights on 
the synergistic/antagonistic activity. We evaluated only concentrations 
of antibiotics that could reveal a synergistic effect based on the 
MBEC values of the single antibiotics to be combined. For MBEC 
>1,024  μg/ml, a fixed value of 1,024  μg/ml was considered for 
the calculation of the FBEC index, thus some combinations which 
were interpreted as not synergistic could turn out to have a 
synergistic effect considering higher MBEC values. However, with 
this approach, the observed positive synergistic effects of antibiotic 
combinations are certain and usually presenting considerably lower 
MBEC values compared to the MBEC values of single antibiotics, 
which are difficult to reach in clinical practice.
The three tested antibiotic combinations showed synergistic 
activity, to varying degrees, against different clinical strains from 
both species partially differing from the results observed with 
the ATCC strains. The considerable reduction of MBEC values 
with antibiotic combinations ranging from 2-fold to 16-fold in 
case of P. aeruginosa strains or 2-fold to 128-fold in case of E. 
coli strains compared to single drug was predominantly in the 
range, which is achievable by intravenous or oral antibiotic 
administration (Dijkmans et  al., 2017; Thabit et  al., 2019).
Even though several studies have reported that fosfomycin 
showed an estimable synergistic effect, among others, with 
TABLE 3 | MIC of E. coli by Etest.
Antimicrobial Ec1 Ec2 Ec3 Ec4 Ec5 Ec6 Ec7 Ec8
Fosfomycin 0.19 0.094 0.125 0.064 0.75 0.25 128(R) 64(R)
Ciprofloxacin 0.016 0.016 0.008 0.008 0.008 8(R) 8(R) 0.008
Gentamicin 1 0.5 1 2 1 96(R) 1 96(R)
MIC values are expressed in μg/ml; R, resistant (according to CLSI).
TABLE 4 | MIC of P. aeruginosa by Etest.
Antimicrobial Pa1 Pa2 Pa3 Pa4 Pa5 Pa6 Pa7
Fosfomycin 32 48 8 16 32 24 48
Ciprofloxacin 0.19 0.064 0.125 0.125 0.094 0.19 12(R)
Gentamicin 1.5 1.5 2 3 2 128(R) 1.5
MIC values are expressed in μg/ml; R, resistant (according to CLSI).
TABLE 6 | MBEC for fosfomycin (FOS), ciprofloxacin (CIP), gentamicin (GEN), and their combinations against P. aeruginosa clinical strains.
Strain
MBEC (FBEC, interpretation)
FOS CIP GEN FOS + CIP FOS + GEN GEN + CIP
Pa1 >1,024 4 8 128* + 1 (0.38, S) 128* + 2 (0.375, S) 2 + 1 (0.5, S)
Pa2 >1,024 32 32 256* + 16 (0.75, NS) 64* + 4 (0.19, S) 4 + 2 (0.19, S)
Pa3 >1,024 16 16 128* + 2 (0.25, S) 128* + 1 (0.19, S) 1 + 1 (0.13, S)
Pa4 >1,024 8 16 32* + 2 (0.28, S) 64* + 1 (0.13, S) 4 + 1 (0.38, S)
Pa5 >1,024 256 128 256* + 128 (0.75, NS) 256* + 64 (0.75, NS) 16 + 32 (0.25, S)
Pa6 >1,024 16 >1,024 64* + 4 (0.31, S) >256* + 256*(>0.5, NS) >256* + 4 (>0.5, NS)
Pa7 >1,024 >1,024 16 >256* + 256*(>0.5, NS) >256* + 4 (>0.5, NS) >4 + 256*(>0.5, NS)
MBEC, minimal biofilm eradication concentration (values are expressed in μg/ml). FBEC, fractional biofilm eradication concentration; S, synergism; NS, no synergism; *MBBC was 
considered equal to 1,024 μg/ml for FBEC calculations.
TABLE 5 | MBEC for fosfomycin (FOS), ciprofloxacin (CIP), gentamicin (GEN), and their combinations against E. coli clinical strains.
Strain
MBEC (FBEC, interpretation)
FOS CIP GEN FOS + CIP FOS + GEN GEN + CIP
Ec1 16 4 16 4 + 2 (0.75, NS) 1 + 1 (0.125, S) 0.5 + 0.5 (0.16, S)
Ec2 4 64 8 0.5 + 2 (0.16, S) 0.5 + 1 (0.25, S) 1 + 2 (0.16, S)
Ec3 16 0.032 8 4 + 0.016 (0.75, NS) 2 + 1 (0.25, S) 2 + 0.016 (0.75, NS)
Ec4 8 0.032 8 2 + 0.016 (0.75, NS) 2 + 0.5 (0.31, S) 2 + 0.016 (0.75, NS)
Ec5 8 64 16 2 + 1 (0.27, S) 1 + 1 (0.19, S) 4 + 0.5 (0.26, S)
Ec6 16 >1,024 >1,024 >4 + 256* (>0.5, NS) 2 + 16* (0.14, S) >256* + 256* (>0.5, NS)
Ec7 >1,024 >1,024 4 >256* + 256*(>0.5, NS) >256* + 1 (>0.5, NS) >1 + 256* (>0.5, NS)
Ec8 >1,024 8 >1,024 >256* + 2 (>0.5, NS) >256* + 256*(>0.5, NS) >256* + 2 (>0.5, NS)
MBEC, minimal biofilm eradication concentration (values are expressed in μg/ml). FBEC, fractional biofilm eradication concentration; S, synergism; NS, no synergism; *MBBC was 
considered equal to 1,024 μg/ml for FBEC calculations.
Wang et al. Antimicrobial Activity Against GN Biofilms
Frontiers in Microbiology | www.frontiersin.org 9 November 2019 | Volume 10 | Article 2522
gentamicin and ciprofloxacin against P. aeruginosa planktonic cells 
(Kastoris et al., 2010), there is limited evidence for these combinations 
against biofilms. The fosfomycin/ciprofloxacin combination has 
being shown to be effective against P. aeruginosa biofilms in other 
experimental set-ups (Xiong et  al., 1995; Mikuniya et  al., 2005), 
whereas we  could not find studies investigating the fosfomycin/
gentamicin combination. Nonetheless, previous studies have shown 
synergistic effect when fosfomycin was combined with other 
aminoglycosides (Cai et  al., 2009; Anderson et  al., 2013) as well 
as other fluoroquinolones (Kumon et  al., 1995; Monden et  al., 
2002; Mikuniya et  al., 2005, 2007) against P. aeruginosa biofilms.
Some authors propose that fosfomycin alters the membrane 
permeability of P. aeruginosa by affecting cell wall synthesis, 
which should lead to enhanced uptake of the fluoroquinolone 
ofloxacin (Monden et  al., 2002). On the other hand, one study 
has suggested that the role of ciprofloxacin is thought to be related 
to damage of the outer membrane, enhancing fosfomycin 
penetration (Yamada et  al., 2007). Regarding permeability in 
biofilms, it was reported that ciprofloxacin had a higher penetration 
rate (>75%) than gentamicin (73%) in P. aeruginosa biofilms 
(Abdi-Ali et al., 2006), but showed a similar kinetic of penetration 
than fosfomycin into the bacterial biofilm of both, E. coli and 
P. aeruginosa species (Rodríguez-Martínez et  al., 2007). Based 
on these studies, it can be  argued that all three antibiotics are 
able to penetrate well into biofilms. Thus, it could be hypothesized 
that the differences observed on the ability of each antibiotic 
combination to exert a synergistic effect might be  attributed to 
other factors, such as killing of persister cells as proposed for 
streptococci in combinations including gentamicin (Gonzalez 
Moreno et al., 2017), rather than the enhancement of penetration. 
Further studies are required to clarify the underlying mechanism 
of their synergistic effect on biofilms.
The fosfomycin/gentamicin combination was the most active 
against E. coli strains. These results also correlate with the 
findings from Corvec et  al., where fosfomycin plus gentamicin 
presented a significant high cure rate in an in vivo foreign-
body infection model (Corvec et  al., 2013). Moreover, the 
fosfomycin/gentamicin combination showed a synergistic effect 
toward a gentamicin-resistant strain, but the same combination 
was not synergistic toward a fosfomycin-resistant strain. 
Conventionally, the mechanism of action of gentamicin has 
been considered at the 30S ribosomal level. Nevertheless, some 
authors have suggested that gentamicin has two potentially 
lethal effects on Gram-negative cells, one being the inhibition 
of protein synthesis and the other one being the surface 
perturbation (Kadurugamuwa et al., 1993a,b). Thus, a bacteriolysis 
effect mediated through perturbation of the cell surface by 
gentamicin could explain the synergism observed by the 
fosfomycin/gentamicin combination toward a gentamicin-
resistant strain. It could be  speculated that, in the case of a 
gentamicin-resistant but fosfomycin-susceptible strain, while 
fosfomycin can act against susceptible bacterial cells, gentamicin 
could also actively target resistant bacterial cells through 
bacteriolysis, resulting in complete biofilm eradication. However, 
in the case of a gentamicin-susceptible but fosfomycin-resistant 
strain, no synergistic effect is observed because only gentamicin 
can act against bacteria, whereas fosfomycin becomes ineffective. 
The two antimicrobial effects of gentamicin might also explain 
why combinations with this antibiotic seem to be  particularly 
effective. Still, elucidations for synergistic effect based on 
planktonic findings would need to be confirmed also for biofilms.
In conclusion, the use of fosfomycin in combination with 
gentamicin seems to be a promising therapeutic approach against 
E. coli biofilm related infections. Nevertheless, against both Gram-
negative species, combination of gentamicin with ciprofloxacin 
represents the most optimal treatment option. Further in vivo 
and clinical studies are essential to define the potential treatment 
regimen based on the combination of these two antibiotics. 
Moreover, our study presents IMC as a sensitive technique to 
provide reliable data on as important field of clinical microbiology 
as it is the screening for biofilm-eradicating approaches.
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